Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Core Insights - Turnstone Biologics is advancing its next-generation Selected Tumor-Infiltrating Lymphocyte (TIL) technology aimed at selectively expanding potent tumor-reactive T cells for solid tumor treatment [1][5] - The company is presenting preclinical data at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, showcasing methods for TIL selection [1][2] Company Overview - Turnstone Biologics is a clinical-stage biotechnology company focused on developing Selected TIL therapy to treat solid tumors, overcoming limitations of first-generation TIL therapies [5][6] - The clinical program TIDAL-01 is currently in multiple Phase 1 studies targeting colorectal cancer, head and neck cancer, and uveal melanoma [5][6] Research Findings - A study in collaboration with H. Lee Moffitt Cancer Center demonstrated successful TIL expansion from gastric tumors using tumor-specific neoantigens, enhancing adoptive cell therapy for solid tumors [3] - Another study in collaboration with the University of Montreal Hospital Research Centre indicated that the overlap between circulating and intratumoral T cell repertoires could predict the expansion of tumor-reactive TILs [4]